Pharma & Healthcare
Global Peptide Vaccine for Tumor Market Research Report 2026
- Mar 17, 26
- ID: 741811
- Pages: 110
- Figures: 116
- Views: 2
This report delivers a comprehensive overview of the global Peptide Vaccine for Tumor market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Peptide Vaccine for Tumor. The Peptide Vaccine for Tumor market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Peptide Vaccine for Tumor market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Peptide Vaccine for Tumor manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AmbioPharm
Almac
ACT
Ultimovacs
Marker Therapeutics, Inc.
Immatics
OncoPep
Anergis
Sellas Life Sciences
Segment by Type
Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Others
by Application
Infectious Disease Prevention
Cancer Immunotherapy
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Peptide Vaccine for Tumor manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Peptide Vaccine for Tumor sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Peptide Vaccine for Tumor market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Peptide Vaccine for Tumor manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AmbioPharm
Almac
ACT
Ultimovacs
Marker Therapeutics, Inc.
Immatics
OncoPep
Anergis
Sellas Life Sciences
Segment by Type
Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Others
by Application
Infectious Disease Prevention
Cancer Immunotherapy
Others
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Peptide Vaccine for Tumor manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Peptide Vaccine for Tumor sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Peptide Vaccine for Tumor Market Overview
1.1 Product Definition
1.2 Peptide Vaccine for Tumor by Type
1.2.1 Global Peptide Vaccine for Tumor Market Value by Type: 2025 vs 2032
1.2.2 Synthetic Polypeptide Vaccines
1.2.3 Recombinant Polypeptide Vaccine
1.2.4 Others
1.3 Peptide Vaccine for Tumor by Application
1.3.1 Global Peptide Vaccine for Tumor Market Value by Application: 2025 vs 2032
1.3.2 Infectious Disease Prevention
1.3.3 Cancer Immunotherapy
1.3.4 Others
1.4 Global Peptide Vaccine for Tumor Market Size Estimates and Forecasts
1.4.1 Global Peptide Vaccine for Tumor Revenue 2021–2032
1.4.2 Global Peptide Vaccine for Tumor Sales 2021–2032
1.4.3 Global Peptide Vaccine for Tumor Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Peptide Vaccine for Tumor Market Competition by Manufacturers
2.1 Global Peptide Vaccine for Tumor Sales Market Share by Manufacturers (2021–2026)
2.2 Global Peptide Vaccine for Tumor Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Peptide Vaccine for Tumor Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Peptide Vaccine for Tumor, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Peptide Vaccine for Tumor, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Peptide Vaccine for Tumor, Product Types and Applications
2.7 Global Key Manufacturers of Peptide Vaccine for Tumor, Date of Entry into the Industry
2.8 Global Peptide Vaccine for Tumor Market Competitive Situation and Trends
2.8.1 Global Peptide Vaccine for Tumor Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Peptide Vaccine for Tumor Players Market Share by Revenue
2.8.3 Global Peptide Vaccine for Tumor Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Peptide Vaccine for Tumor Market Scenario by Region
3.1 Global Peptide Vaccine for Tumor Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Peptide Vaccine for Tumor Sales by Region: 2021–2032
3.2.1 Global Peptide Vaccine for Tumor Sales by Region: 2021–2026
3.2.2 Global Peptide Vaccine for Tumor Sales by Region: 2027–2032
3.3 Global Peptide Vaccine for Tumor Revenue by Region: 2021–2032
3.3.1 Global Peptide Vaccine for Tumor Revenue by Region: 2021–2026
3.3.2 Global Peptide Vaccine for Tumor Revenue by Region: 2027–2032
3.4 North America Peptide Vaccine for Tumor Market Facts & Figures by Country
3.4.1 North America Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.4.3 North America Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Peptide Vaccine for Tumor Market Facts & Figures by Country
3.5.1 Europe Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.5.3 Europe Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide Vaccine for Tumor Market Facts & Figures by Region
3.6.1 Asia Pacific Peptide Vaccine for Tumor Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Peptide Vaccine for Tumor Sales by Region (2021–2032)
3.6.3 Asia Pacific Peptide Vaccine for Tumor Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Peptide Vaccine for Tumor Market Facts & Figures by Country
3.7.1 Latin America Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.7.3 Latin America Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Peptide Vaccine for Tumor Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.8.3 Middle East and Africa Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Peptide Vaccine for Tumor Sales by Type (2021–2032)
4.1.1 Global Peptide Vaccine for Tumor Sales by Type (2021–2026)
4.1.2 Global Peptide Vaccine for Tumor Sales by Type (2027–2032)
4.1.3 Global Peptide Vaccine for Tumor Sales Market Share by Type (2021–2032)
4.2 Global Peptide Vaccine for Tumor Revenue by Type (2021–2032)
4.2.1 Global Peptide Vaccine for Tumor Revenue by Type (2021–2026)
4.2.2 Global Peptide Vaccine for Tumor Revenue by Type (2027–2032)
4.2.3 Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021–2032)
4.3 Global Peptide Vaccine for Tumor Price by Type (2021–2032)
5 Segment by Application
5.1 Global Peptide Vaccine for Tumor Sales by Application (2021–2032)
5.1.1 Global Peptide Vaccine for Tumor Sales by Application (2021–2026)
5.1.2 Global Peptide Vaccine for Tumor Sales by Application (2027–2032)
5.1.3 Global Peptide Vaccine for Tumor Sales Market Share by Application (2021–2032)
5.2 Global Peptide Vaccine for Tumor Revenue by Application (2021–2032)
5.2.1 Global Peptide Vaccine for Tumor Revenue by Application (2021–2026)
5.2.2 Global Peptide Vaccine for Tumor Revenue by Application (2027–2032)
5.2.3 Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021–2032)
5.3 Global Peptide Vaccine for Tumor Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AmbioPharm
6.1.1 AmbioPharm Company Information
6.1.2 AmbioPharm Description and Business Overview
6.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AmbioPharm Peptide Vaccine for Tumor Product Portfolio
6.1.5 AmbioPharm Recent Developments/Updates
6.2 Almac
6.2.1 Almac Company Information
6.2.2 Almac Description and Business Overview
6.2.3 Almac Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Almac Peptide Vaccine for Tumor Product Portfolio
6.2.5 Almac Recent Developments/Updates
6.3 ACT
6.3.1 ACT Company Information
6.3.2 ACT Description and Business Overview
6.3.3 ACT Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 ACT Peptide Vaccine for Tumor Product Portfolio
6.3.5 ACT Recent Developments/Updates
6.4 Ultimovacs
6.4.1 Ultimovacs Company Information
6.4.2 Ultimovacs Description and Business Overview
6.4.3 Ultimovacs Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Ultimovacs Peptide Vaccine for Tumor Product Portfolio
6.4.5 Ultimovacs Recent Developments/Updates
6.5 Marker Therapeutics, Inc.
6.5.1 Marker Therapeutics, Inc. Company Information
6.5.2 Marker Therapeutics, Inc. Description and Business Overview
6.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio
6.5.5 Marker Therapeutics, Inc. Recent Developments/Updates
6.6 Immatics
6.6.1 Immatics Company Information
6.6.2 Immatics Description and Business Overview
6.6.3 Immatics Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Immatics Peptide Vaccine for Tumor Product Portfolio
6.6.5 Immatics Recent Developments/Updates
6.7 OncoPep
6.7.1 OncoPep Company Information
6.7.2 OncoPep Description and Business Overview
6.7.3 OncoPep Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 OncoPep Peptide Vaccine for Tumor Product Portfolio
6.7.5 OncoPep Recent Developments/Updates
6.8 Anergis
6.8.1 Anergis Company Information
6.8.2 Anergis Description and Business Overview
6.8.3 Anergis Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Anergis Peptide Vaccine for Tumor Product Portfolio
6.8.5 Anergis Recent Developments/Updates
6.9 Sellas Life Sciences
6.9.1 Sellas Life Sciences Company Information
6.9.2 Sellas Life Sciences Description and Business Overview
6.9.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio
6.9.5 Sellas Life Sciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide Vaccine for Tumor Industry Chain Analysis
7.2 Peptide Vaccine for Tumor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide Vaccine for Tumor Production Mode & Process Analysis
7.4 Peptide Vaccine for Tumor Sales and Marketing
7.4.1 Peptide Vaccine for Tumor Sales Channels
7.4.2 Peptide Vaccine for Tumor Distributors
7.5 Peptide Vaccine for Tumor Customer Analysis
8 Peptide Vaccine for Tumor Market Dynamics
8.1 Peptide Vaccine for Tumor Industry Trends
8.2 Peptide Vaccine for Tumor Market Drivers
8.3 Peptide Vaccine for Tumor Market Challenges
8.4 Peptide Vaccine for Tumor Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Peptide Vaccine for Tumor by Type
1.2.1 Global Peptide Vaccine for Tumor Market Value by Type: 2025 vs 2032
1.2.2 Synthetic Polypeptide Vaccines
1.2.3 Recombinant Polypeptide Vaccine
1.2.4 Others
1.3 Peptide Vaccine for Tumor by Application
1.3.1 Global Peptide Vaccine for Tumor Market Value by Application: 2025 vs 2032
1.3.2 Infectious Disease Prevention
1.3.3 Cancer Immunotherapy
1.3.4 Others
1.4 Global Peptide Vaccine for Tumor Market Size Estimates and Forecasts
1.4.1 Global Peptide Vaccine for Tumor Revenue 2021–2032
1.4.2 Global Peptide Vaccine for Tumor Sales 2021–2032
1.4.3 Global Peptide Vaccine for Tumor Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Peptide Vaccine for Tumor Market Competition by Manufacturers
2.1 Global Peptide Vaccine for Tumor Sales Market Share by Manufacturers (2021–2026)
2.2 Global Peptide Vaccine for Tumor Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Peptide Vaccine for Tumor Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Peptide Vaccine for Tumor, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Peptide Vaccine for Tumor, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Peptide Vaccine for Tumor, Product Types and Applications
2.7 Global Key Manufacturers of Peptide Vaccine for Tumor, Date of Entry into the Industry
2.8 Global Peptide Vaccine for Tumor Market Competitive Situation and Trends
2.8.1 Global Peptide Vaccine for Tumor Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Peptide Vaccine for Tumor Players Market Share by Revenue
2.8.3 Global Peptide Vaccine for Tumor Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Peptide Vaccine for Tumor Market Scenario by Region
3.1 Global Peptide Vaccine for Tumor Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Peptide Vaccine for Tumor Sales by Region: 2021–2032
3.2.1 Global Peptide Vaccine for Tumor Sales by Region: 2021–2026
3.2.2 Global Peptide Vaccine for Tumor Sales by Region: 2027–2032
3.3 Global Peptide Vaccine for Tumor Revenue by Region: 2021–2032
3.3.1 Global Peptide Vaccine for Tumor Revenue by Region: 2021–2026
3.3.2 Global Peptide Vaccine for Tumor Revenue by Region: 2027–2032
3.4 North America Peptide Vaccine for Tumor Market Facts & Figures by Country
3.4.1 North America Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.4.3 North America Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Peptide Vaccine for Tumor Market Facts & Figures by Country
3.5.1 Europe Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.5.3 Europe Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Peptide Vaccine for Tumor Market Facts & Figures by Region
3.6.1 Asia Pacific Peptide Vaccine for Tumor Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Peptide Vaccine for Tumor Sales by Region (2021–2032)
3.6.3 Asia Pacific Peptide Vaccine for Tumor Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Peptide Vaccine for Tumor Market Facts & Figures by Country
3.7.1 Latin America Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.7.3 Latin America Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Peptide Vaccine for Tumor Market Facts & Figures by Country
3.8.1 Middle East and Africa Peptide Vaccine for Tumor Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Peptide Vaccine for Tumor Sales by Country (2021–2032)
3.8.3 Middle East and Africa Peptide Vaccine for Tumor Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Peptide Vaccine for Tumor Sales by Type (2021–2032)
4.1.1 Global Peptide Vaccine for Tumor Sales by Type (2021–2026)
4.1.2 Global Peptide Vaccine for Tumor Sales by Type (2027–2032)
4.1.3 Global Peptide Vaccine for Tumor Sales Market Share by Type (2021–2032)
4.2 Global Peptide Vaccine for Tumor Revenue by Type (2021–2032)
4.2.1 Global Peptide Vaccine for Tumor Revenue by Type (2021–2026)
4.2.2 Global Peptide Vaccine for Tumor Revenue by Type (2027–2032)
4.2.3 Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021–2032)
4.3 Global Peptide Vaccine for Tumor Price by Type (2021–2032)
5 Segment by Application
5.1 Global Peptide Vaccine for Tumor Sales by Application (2021–2032)
5.1.1 Global Peptide Vaccine for Tumor Sales by Application (2021–2026)
5.1.2 Global Peptide Vaccine for Tumor Sales by Application (2027–2032)
5.1.3 Global Peptide Vaccine for Tumor Sales Market Share by Application (2021–2032)
5.2 Global Peptide Vaccine for Tumor Revenue by Application (2021–2032)
5.2.1 Global Peptide Vaccine for Tumor Revenue by Application (2021–2026)
5.2.2 Global Peptide Vaccine for Tumor Revenue by Application (2027–2032)
5.2.3 Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021–2032)
5.3 Global Peptide Vaccine for Tumor Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AmbioPharm
6.1.1 AmbioPharm Company Information
6.1.2 AmbioPharm Description and Business Overview
6.1.3 AmbioPharm Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AmbioPharm Peptide Vaccine for Tumor Product Portfolio
6.1.5 AmbioPharm Recent Developments/Updates
6.2 Almac
6.2.1 Almac Company Information
6.2.2 Almac Description and Business Overview
6.2.3 Almac Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Almac Peptide Vaccine for Tumor Product Portfolio
6.2.5 Almac Recent Developments/Updates
6.3 ACT
6.3.1 ACT Company Information
6.3.2 ACT Description and Business Overview
6.3.3 ACT Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 ACT Peptide Vaccine for Tumor Product Portfolio
6.3.5 ACT Recent Developments/Updates
6.4 Ultimovacs
6.4.1 Ultimovacs Company Information
6.4.2 Ultimovacs Description and Business Overview
6.4.3 Ultimovacs Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Ultimovacs Peptide Vaccine for Tumor Product Portfolio
6.4.5 Ultimovacs Recent Developments/Updates
6.5 Marker Therapeutics, Inc.
6.5.1 Marker Therapeutics, Inc. Company Information
6.5.2 Marker Therapeutics, Inc. Description and Business Overview
6.5.3 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product Portfolio
6.5.5 Marker Therapeutics, Inc. Recent Developments/Updates
6.6 Immatics
6.6.1 Immatics Company Information
6.6.2 Immatics Description and Business Overview
6.6.3 Immatics Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Immatics Peptide Vaccine for Tumor Product Portfolio
6.6.5 Immatics Recent Developments/Updates
6.7 OncoPep
6.7.1 OncoPep Company Information
6.7.2 OncoPep Description and Business Overview
6.7.3 OncoPep Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 OncoPep Peptide Vaccine for Tumor Product Portfolio
6.7.5 OncoPep Recent Developments/Updates
6.8 Anergis
6.8.1 Anergis Company Information
6.8.2 Anergis Description and Business Overview
6.8.3 Anergis Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Anergis Peptide Vaccine for Tumor Product Portfolio
6.8.5 Anergis Recent Developments/Updates
6.9 Sellas Life Sciences
6.9.1 Sellas Life Sciences Company Information
6.9.2 Sellas Life Sciences Description and Business Overview
6.9.3 Sellas Life Sciences Peptide Vaccine for Tumor Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Sellas Life Sciences Peptide Vaccine for Tumor Product Portfolio
6.9.5 Sellas Life Sciences Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Peptide Vaccine for Tumor Industry Chain Analysis
7.2 Peptide Vaccine for Tumor Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Peptide Vaccine for Tumor Production Mode & Process Analysis
7.4 Peptide Vaccine for Tumor Sales and Marketing
7.4.1 Peptide Vaccine for Tumor Sales Channels
7.4.2 Peptide Vaccine for Tumor Distributors
7.5 Peptide Vaccine for Tumor Customer Analysis
8 Peptide Vaccine for Tumor Market Dynamics
8.1 Peptide Vaccine for Tumor Industry Trends
8.2 Peptide Vaccine for Tumor Market Drivers
8.3 Peptide Vaccine for Tumor Market Challenges
8.4 Peptide Vaccine for Tumor Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Peptide Vaccine for Tumor Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Peptide Vaccine for Tumor Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Peptide Vaccine for Tumor Market Competitive Situation by Manufacturers in 2025
Table 4. Global Peptide Vaccine for Tumor Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Peptide Vaccine for Tumor Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Peptide Vaccine for Tumor Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Peptide Vaccine for Tumor Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Peptide Vaccine for Tumor, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Peptide Vaccine for Tumor, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Peptide Vaccine for Tumor, Product Types and Applications
Table 12. Global Key Manufacturers of Peptide Vaccine for Tumor, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Peptide Vaccine for Tumor Companies by Tier (Tier 1, Tier 2, Tier 3), based on Peptide Vaccine for Tumor Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Peptide Vaccine for Tumor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Peptide Vaccine for Tumor Sales by Region (K Dose), 2021–2026
Table 18. Global Peptide Vaccine for Tumor Sales Market Share by Region (2021–2026)
Table 19. Global Peptide Vaccine for Tumor Sales by Region (K Dose), 2027–2032
Table 20. Global Peptide Vaccine for Tumor Sales Market Share by Region (2027–2032)
Table 21. Global Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2021–2026
Table 22. Global Peptide Vaccine for Tumor Revenue Market Share by Region (2021–2026)
Table 23. Global Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2027–2032
Table 24. Global Peptide Vaccine for Tumor Revenue Market Share by Region (2027–2032)
Table 25. North America Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 27. North America Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 28. North America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 29. North America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 32. Europe Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 33. Europe Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Peptide Vaccine for Tumor Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Peptide Vaccine for Tumor Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Peptide Vaccine for Tumor Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 42. Latin America Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 43. Latin America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 50. Global Peptide Vaccine for Tumor Sales (K Dose) by Type (2021–2026)
Table 51. Global Peptide Vaccine for Tumor Sales (K Dose) by Type (2027–2032)
Table 52. Global Peptide Vaccine for Tumor Sales Market Share by Type (2021–2026)
Table 53. Global Peptide Vaccine for Tumor Sales Market Share by Type (2027–2032)
Table 54. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021–2026)
Table 57. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2027–2032)
Table 58. Global Peptide Vaccine for Tumor Price (US$/Dose) by Type (2021–2026)
Table 59. Global Peptide Vaccine for Tumor Price (US$/Dose) by Type (2027–2032)
Table 60. Global Peptide Vaccine for Tumor Sales (K Dose) by Application (2021–2026)
Table 61. Global Peptide Vaccine for Tumor Sales (K Dose) by Application (2027–2032)
Table 62. Global Peptide Vaccine for Tumor Sales Market Share by Application (2021–2026)
Table 63. Global Peptide Vaccine for Tumor Sales Market Share by Application (2027–2032)
Table 64. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021–2026)
Table 67. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2027–2032)
Table 68. Global Peptide Vaccine for Tumor Price (US$/Dose) by Application (2021–2026)
Table 69. Global Peptide Vaccine for Tumor Price (US$/Dose) by Application (2027–2032)
Table 70. AmbioPharm Company Information
Table 71. AmbioPharm Description and Business Overview
Table 72. AmbioPharm Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. AmbioPharm Peptide Vaccine for Tumor Product
Table 74. AmbioPharm Recent Developments/Updates
Table 75. Almac Company Information
Table 76. Almac Description and Business Overview
Table 77. Almac Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Almac Peptide Vaccine for Tumor Product
Table 79. Almac Recent Developments/Updates
Table 80. ACT Company Information
Table 81. ACT Description and Business Overview
Table 82. ACT Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. ACT Peptide Vaccine for Tumor Product
Table 84. ACT Recent Developments/Updates
Table 85. Ultimovacs Company Information
Table 86. Ultimovacs Description and Business Overview
Table 87. Ultimovacs Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Ultimovacs Peptide Vaccine for Tumor Product
Table 89. Ultimovacs Recent Developments/Updates
Table 90. Marker Therapeutics, Inc. Company Information
Table 91. Marker Therapeutics, Inc. Description and Business Overview
Table 92. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product
Table 94. Marker Therapeutics, Inc. Recent Developments/Updates
Table 95. Immatics Company Information
Table 96. Immatics Description and Business Overview
Table 97. Immatics Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Immatics Peptide Vaccine for Tumor Product
Table 99. Immatics Recent Developments/Updates
Table 100. OncoPep Company Information
Table 101. OncoPep Description and Business Overview
Table 102. OncoPep Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. OncoPep Peptide Vaccine for Tumor Product
Table 104. OncoPep Recent Developments/Updates
Table 105. Anergis Company Information
Table 106. Anergis Description and Business Overview
Table 107. Anergis Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Anergis Peptide Vaccine for Tumor Product
Table 109. Anergis Recent Developments/Updates
Table 110. Sellas Life Sciences Company Information
Table 111. Sellas Life Sciences Description and Business Overview
Table 112. Sellas Life Sciences Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Sellas Life Sciences Peptide Vaccine for Tumor Product
Table 114. Sellas Life Sciences Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Peptide Vaccine for Tumor Distributors List
Table 118. Peptide Vaccine for Tumor Customers List
Table 119. Peptide Vaccine for Tumor Market Trends
Table 120. Peptide Vaccine for Tumor Market Drivers
Table 121. Peptide Vaccine for Tumor Market Challenges
Table 122. Peptide Vaccine for Tumor Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Peptide Vaccine for Tumor
Figure 2. Global Peptide Vaccine for Tumor Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Peptide Vaccine for Tumor Market Share by Type: 2025 & 2032
Figure 4. Synthetic Polypeptide Vaccines Product Picture
Figure 5. Recombinant Polypeptide Vaccine Product Picture
Figure 6. Others Product Picture
Figure 7. Global Peptide Vaccine for Tumor Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Peptide Vaccine for Tumor Market Share by Application: 2025 & 2032
Figure 9. Infectious Disease Prevention
Figure 10. Cancer Immunotherapy
Figure 11. Others
Figure 12. Global Peptide Vaccine for Tumor Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Peptide Vaccine for Tumor Market Size (US$ Million), 2021–2032
Figure 14. Global Peptide Vaccine for Tumor Sales (K Dose), 2021–2032
Figure 15. Global Peptide Vaccine for Tumor Average Price (US$/Dose), 2021–2032
Figure 16. Peptide Vaccine for Tumor Report Years Considered
Figure 17. Peptide Vaccine for Tumor Sales Share by Manufacturers in 2025
Figure 18. Global Peptide Vaccine for Tumor Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Peptide Vaccine for Tumor Players: Market Share by Revenue in Peptide Vaccine for Tumor in 2025
Figure 20. Peptide Vaccine for Tumor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Peptide Vaccine for Tumor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 23. North America Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 24. United States Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 27. Europe Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 28. Germany Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Peptide Vaccine for Tumor Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Peptide Vaccine for Tumor Revenue Market Share by Region (2021–2032)
Figure 35. China Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 43. Latin America Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Peptide Vaccine for Tumor by Type (2021–2032)
Figure 54. Global Revenue Market Share of Peptide Vaccine for Tumor by Type (2021–2032)
Figure 55. Global Peptide Vaccine for Tumor Price (US$/Dose) by Type (2021–2032)
Figure 56. Global Sales Market Share of Peptide Vaccine for Tumor by Application (2021–2032)
Figure 57. Global Revenue Market Share of Peptide Vaccine for Tumor by Application (2021–2032)
Figure 58. Global Peptide Vaccine for Tumor Price (US$/Dose) by Application (2021–2032)
Figure 59. Peptide Vaccine for Tumor Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Peptide Vaccine for Tumor Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Peptide Vaccine for Tumor Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Peptide Vaccine for Tumor Market Competitive Situation by Manufacturers in 2025
Table 4. Global Peptide Vaccine for Tumor Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Peptide Vaccine for Tumor Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Peptide Vaccine for Tumor Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Peptide Vaccine for Tumor Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Peptide Vaccine for Tumor, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Peptide Vaccine for Tumor, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Peptide Vaccine for Tumor, Product Types and Applications
Table 12. Global Key Manufacturers of Peptide Vaccine for Tumor, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Peptide Vaccine for Tumor Companies by Tier (Tier 1, Tier 2, Tier 3), based on Peptide Vaccine for Tumor Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Peptide Vaccine for Tumor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Peptide Vaccine for Tumor Sales by Region (K Dose), 2021–2026
Table 18. Global Peptide Vaccine for Tumor Sales Market Share by Region (2021–2026)
Table 19. Global Peptide Vaccine for Tumor Sales by Region (K Dose), 2027–2032
Table 20. Global Peptide Vaccine for Tumor Sales Market Share by Region (2027–2032)
Table 21. Global Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2021–2026
Table 22. Global Peptide Vaccine for Tumor Revenue Market Share by Region (2021–2026)
Table 23. Global Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2027–2032
Table 24. Global Peptide Vaccine for Tumor Revenue Market Share by Region (2027–2032)
Table 25. North America Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 27. North America Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 28. North America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 29. North America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 32. Europe Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 33. Europe Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Peptide Vaccine for Tumor Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Peptide Vaccine for Tumor Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Peptide Vaccine for Tumor Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Peptide Vaccine for Tumor Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 42. Latin America Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 43. Latin America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Peptide Vaccine for Tumor Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Peptide Vaccine for Tumor Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Peptide Vaccine for Tumor Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Peptide Vaccine for Tumor Revenue by Country (US$ Million), 2027–2032
Table 50. Global Peptide Vaccine for Tumor Sales (K Dose) by Type (2021–2026)
Table 51. Global Peptide Vaccine for Tumor Sales (K Dose) by Type (2027–2032)
Table 52. Global Peptide Vaccine for Tumor Sales Market Share by Type (2021–2026)
Table 53. Global Peptide Vaccine for Tumor Sales Market Share by Type (2027–2032)
Table 54. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2021–2026)
Table 57. Global Peptide Vaccine for Tumor Revenue Market Share by Type (2027–2032)
Table 58. Global Peptide Vaccine for Tumor Price (US$/Dose) by Type (2021–2026)
Table 59. Global Peptide Vaccine for Tumor Price (US$/Dose) by Type (2027–2032)
Table 60. Global Peptide Vaccine for Tumor Sales (K Dose) by Application (2021–2026)
Table 61. Global Peptide Vaccine for Tumor Sales (K Dose) by Application (2027–2032)
Table 62. Global Peptide Vaccine for Tumor Sales Market Share by Application (2021–2026)
Table 63. Global Peptide Vaccine for Tumor Sales Market Share by Application (2027–2032)
Table 64. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Peptide Vaccine for Tumor Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2021–2026)
Table 67. Global Peptide Vaccine for Tumor Revenue Market Share by Application (2027–2032)
Table 68. Global Peptide Vaccine for Tumor Price (US$/Dose) by Application (2021–2026)
Table 69. Global Peptide Vaccine for Tumor Price (US$/Dose) by Application (2027–2032)
Table 70. AmbioPharm Company Information
Table 71. AmbioPharm Description and Business Overview
Table 72. AmbioPharm Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. AmbioPharm Peptide Vaccine for Tumor Product
Table 74. AmbioPharm Recent Developments/Updates
Table 75. Almac Company Information
Table 76. Almac Description and Business Overview
Table 77. Almac Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Almac Peptide Vaccine for Tumor Product
Table 79. Almac Recent Developments/Updates
Table 80. ACT Company Information
Table 81. ACT Description and Business Overview
Table 82. ACT Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. ACT Peptide Vaccine for Tumor Product
Table 84. ACT Recent Developments/Updates
Table 85. Ultimovacs Company Information
Table 86. Ultimovacs Description and Business Overview
Table 87. Ultimovacs Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Ultimovacs Peptide Vaccine for Tumor Product
Table 89. Ultimovacs Recent Developments/Updates
Table 90. Marker Therapeutics, Inc. Company Information
Table 91. Marker Therapeutics, Inc. Description and Business Overview
Table 92. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 93. Marker Therapeutics, Inc. Peptide Vaccine for Tumor Product
Table 94. Marker Therapeutics, Inc. Recent Developments/Updates
Table 95. Immatics Company Information
Table 96. Immatics Description and Business Overview
Table 97. Immatics Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 98. Immatics Peptide Vaccine for Tumor Product
Table 99. Immatics Recent Developments/Updates
Table 100. OncoPep Company Information
Table 101. OncoPep Description and Business Overview
Table 102. OncoPep Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 103. OncoPep Peptide Vaccine for Tumor Product
Table 104. OncoPep Recent Developments/Updates
Table 105. Anergis Company Information
Table 106. Anergis Description and Business Overview
Table 107. Anergis Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 108. Anergis Peptide Vaccine for Tumor Product
Table 109. Anergis Recent Developments/Updates
Table 110. Sellas Life Sciences Company Information
Table 111. Sellas Life Sciences Description and Business Overview
Table 112. Sellas Life Sciences Peptide Vaccine for Tumor Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 113. Sellas Life Sciences Peptide Vaccine for Tumor Product
Table 114. Sellas Life Sciences Recent Developments/Updates
Table 115. Key Raw Materials Lists
Table 116. Raw Materials Key Suppliers Lists
Table 117. Peptide Vaccine for Tumor Distributors List
Table 118. Peptide Vaccine for Tumor Customers List
Table 119. Peptide Vaccine for Tumor Market Trends
Table 120. Peptide Vaccine for Tumor Market Drivers
Table 121. Peptide Vaccine for Tumor Market Challenges
Table 122. Peptide Vaccine for Tumor Market Restraints
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Product Picture of Peptide Vaccine for Tumor
Figure 2. Global Peptide Vaccine for Tumor Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Peptide Vaccine for Tumor Market Share by Type: 2025 & 2032
Figure 4. Synthetic Polypeptide Vaccines Product Picture
Figure 5. Recombinant Polypeptide Vaccine Product Picture
Figure 6. Others Product Picture
Figure 7. Global Peptide Vaccine for Tumor Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Peptide Vaccine for Tumor Market Share by Application: 2025 & 2032
Figure 9. Infectious Disease Prevention
Figure 10. Cancer Immunotherapy
Figure 11. Others
Figure 12. Global Peptide Vaccine for Tumor Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 13. Global Peptide Vaccine for Tumor Market Size (US$ Million), 2021–2032
Figure 14. Global Peptide Vaccine for Tumor Sales (K Dose), 2021–2032
Figure 15. Global Peptide Vaccine for Tumor Average Price (US$/Dose), 2021–2032
Figure 16. Peptide Vaccine for Tumor Report Years Considered
Figure 17. Peptide Vaccine for Tumor Sales Share by Manufacturers in 2025
Figure 18. Global Peptide Vaccine for Tumor Revenue Share by Manufacturers in 2025
Figure 19. Top 5 and Top 10 Global Peptide Vaccine for Tumor Players: Market Share by Revenue in Peptide Vaccine for Tumor in 2025
Figure 20. Peptide Vaccine for Tumor Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 21. Global Peptide Vaccine for Tumor Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 22. North America Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 23. North America Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 24. United States Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Canada Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 26. Europe Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 27. Europe Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 28. Germany Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. France Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. U.K. Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Italy Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Russia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Asia Pacific Peptide Vaccine for Tumor Sales Market Share by Region (2021–2032)
Figure 34. Asia Pacific Peptide Vaccine for Tumor Revenue Market Share by Region (2021–2032)
Figure 35. China Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. Japan Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. South Korea Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. India Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. Australia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. China Taiwan Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Southeast Asia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Latin America Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 43. Latin America Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 44. Mexico Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Brazil Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Argentina Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Colombia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Middle East and Africa Peptide Vaccine for Tumor Sales Market Share by Country (2021–2032)
Figure 49. Middle East and Africa Peptide Vaccine for Tumor Revenue Market Share by Country (2021–2032)
Figure 50. Turkey Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. Saudi Arabia Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. UAE Peptide Vaccine for Tumor Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Global Sales Market Share of Peptide Vaccine for Tumor by Type (2021–2032)
Figure 54. Global Revenue Market Share of Peptide Vaccine for Tumor by Type (2021–2032)
Figure 55. Global Peptide Vaccine for Tumor Price (US$/Dose) by Type (2021–2032)
Figure 56. Global Sales Market Share of Peptide Vaccine for Tumor by Application (2021–2032)
Figure 57. Global Revenue Market Share of Peptide Vaccine for Tumor by Application (2021–2032)
Figure 58. Global Peptide Vaccine for Tumor Price (US$/Dose) by Application (2021–2032)
Figure 59. Peptide Vaccine for Tumor Value Chain
Figure 60. Channels of Distribution (Direct Vs Distribution)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232